By Chris Wack
Pliant Therapeutics shares were halted in early morning trading after falling 25% to $2.57, after the company said it is discontinuing a phase 2b trial for bexotegrast in patients with idiopathic pulmonary fibrosis.
The discontinuation follows a prespecified data review and recommendation by an independent Data Safety Monitoring Board, as well as a secondary review and recommendation by an outside expert panel.
The late-stage biopharmaceutical company said that while an imbalance in unadjudicated IPF-related adverse events between the treatment and placebo groups led to the discontinuation of the trial, early evidence of efficacy on the forced vital capacity endpoint was also observed.
Overall, the percentage of IPF-related adverse events in both dose groups was comparable--about 10%.
The company plans to analyze the complete data from the trial and evaluate next steps for bexotegrast's development, including additional dose-ranging Phase 2b studies with lower doses in pulmonary fibrosis.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
March 03, 2025 09:47 ET (14:47 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.